In the news: New cancer targets

Since the publication of a recent Nature Oncogene article from our lab (Prof. Peter Lobie, Liggins Institute) uncovering the novel oncogenic functions of a growth factor called Artemin there has been an explosion of media interest.

This has included a couple of news pieces: TVNZ , NZHerald, NZCity

Furthermore Neuren Pharmaceuticals have recently announced the formation of a new spin out venture assisted by funding from the Breast Cancer Research Trust called Perseis Therapeutics Ltd. Since the failure of the glypromate clinical trials they have switched tact to focus on their cancer program (Plan B by the sounds of it). Funny enough these are molecules are also through Prof. Peter Lobie’s laboratory at the Liggins Institute targeting TFF1, TFF3 and human growth hormone.



Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s